Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Alembic Pharma gains after receiving USFDA nod for Larotrectinib Capsules
Alembic Pharmaceuticals advanced 1.15% to Rs 744.95 after the company announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Larotrectinib Capsules.
AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer
AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its import, sale, and distribution for an additional use. The drug will now be available as a first-line treatment for certain types of advanced breast cancer. This development expands treatment options for oncologists and patients facing HER2-positive breast cancer.
Sun Pharma Share Price Live Updates: Sun Pharma Trading Performance
Sun Pharma Share Price Live Updates: Sun Pharma's performance dips in the last month
Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.
SBI steps in with $1-billion funding for Sun Pharma’s Organon deal
The size of SBI’s funding for the $12-billion Sun Pharma-Organon deal underscores the growing appetite among state-run banks to back M&A deals by Indian companies.
SBI in $1 billion funding for Sun Pharma’s US deal
State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.
Sun Pharma Share Price Live Updates: Sun Pharma Sees Increased Trading Activity
Sun Pharma, Ozempic Defy Slowdown In India's Weight-Loss Market
The slowdown is largely attributed to a natural cooling after the rapid patient onboarding seen in April. With a significant portion of early adopters already initiated on therapy, repeat purchases are now emerging as the primary growth driver for the category.
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row - Mint
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a rowMint